Pressure BioSciences (OTCQB: PBIO), a global leader in the development and sale of broadly enabling, high-pressure-based products and services to the life sciences industry, has renewed its partnership with NutraLife Biosciences (OTC: NLBS), a highly respected manufacturer and distributor of nutraceuticals primarily sold on a direct-to-consumer basis. The two companies first began working together four years ago, and this new collaboration is focused on combining PBIO’s best-in-class UltraShear nanoemulsification platform with NLBS’s highly effective nutraceuticals product formulation, marketing, sales and distribution capabilities. The focus of the partnership will be to develop, market and sell a higher-performing line of next-generation nutraceuticals. “Our UltraShear nanoemulsions platform has left initial collaborators across diverse markets awestruck over the potency and economic efficiencies that we can deliver to their customers and to their bottom line,” said Pressure Biosciences president and CEO Richard T. Schumacher in the press release. “Our priority has been to select partners who have the existing networks and infrastructure to ‘hit the ground running’ with the uniquely differentiated, superior product opportunities that we offer and enable for them. [The] team at NLBS are precisely what we seek — ready to leverage their extensive existing customer base and market channels to achieve early and rapidly scaling sales traction for innovative and re-engineered products across the nutraceuticals product frontier. In particular, they have been seeking a truly effective nano-CBD tincture solution — and we have that that product already developed and well proven in the hands of independent external experts.”
To view the full press release, visit https://ibn.fm/uGkdQ
About Pressure BioSciences Inc.
Pressure BioSciences is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. PBIO’s products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented, enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control biomolecular interactions (e.g., cell lysis, biomolecule extraction). The company’s primary focus is the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of PBIO’s pressure-based technologies in the following areas: (1) the use of its recently acquired, patented technology from BaroFold Inc. (the “BaroFold” technology) to allow entry into the biopharma contract services sector, and (2) the use of its recently patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room-temperature, stable, low-acid liquid foods that cannot be effectively preserved using existing nonthermal technologies. For more information, visit the company website at www.PressureBioSciences.com.
NOTE TO INVESTORS: The latest news and updates relating to SYATF are available in the company’s newsroom at http://ibn.fm/PBIO
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork
